

# Real World Clinical Effectiveness & Safety of Vesemnogene Lantu-parvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).

NCT07265232

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3
<b>Sponsor</b>	Lantu Biopharma
<b>Enrollment</b>	15 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Willing and able to give written informed consent for participation in the study.
- Genetic confirmation of SMA (biallelic deletion or mutation of SMN1).
- SMA clinical phenotype and condition, that in the opinion of the treating physician, treatment with Vesemnogene will likely be beneficial.
- Absence of contraindications for spinal tap procedure or administration of intrathecal therapy.
- Total AAV antibody titres  $\leq$  1:20 as determined by ELISA assay.
- ... and 2 more (see full listing online)

### Exclusion (1)

- None

## Locations (1 total)

---

Tzu chi hospital, Jakarta, Indonesia, Indonesia